SOLARA ACTIVE PHARMA SCIENCES LIMITED — Regulatory Filings 2021

May 6, 2021

==> picture [214 x 85] intentionally omitted <==

Communication Address: Solara Active Pharma Sciences Limited Batra Centre No. 28. Sardar Patel Road. Post Box 2630 Guindy. Chennai - 600 032. India Tel : +91 44 43446700. 22207500 Fax : +91 44 22350278 E-mail : investors@solara.com www.solara.co.in

May 6, 2021.

The BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai – 400 051

Scrip Code: 541540

Scrip Code: SOLARA

Dear Sirs,

Sub: Outcome of Board Meeting

Please refer our letter dated April 29, 2021 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, in continuation we wish to inform that at the meeting of Board of Directors held today (May 6, 2021) the Directors has inter-alia, approved the following:

• Audited financial results (standalone and consolidated) of the Company for the quarter and Year ended March 31, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. A copy of the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2021 along with the Auditors report for the said period and press release is attached.

• Recommended dividend of Rs. 3/-per equity share (30%) for the year ended March 31, 2021, subject to the approval of shareholders of the company at the ensuing Annual General Meeting. The dividend will be paid within 30 days from the date of ensuing Annual General Meeting of the Company.

The Board Meeting commenced at 11.30 a.m. and concluded at 2.50 p.m. We request you to take the same on record.

Thanking you, Yours faithfully,

For Solara Active Pharma Sciences Limited

S. Murali Krishna Company Secretary

Encl: as above.

Solara Active Pharma Sciences Limited - CIN : L24230MH2017PLC291636

REGD. OFF: 201, Devavrata, Sector 17, Vashi Navi Mumbai - 400703. India/ Tel: 91-22-2789 2924 / 2789 3199 / Fax: 91-22-2789 2942